Clinical Trials Logo

Clinical Trial Summary

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.


Clinical Trial Description

Bacillus Calmette-Guérin (BCG) has been postulated as a strategy to prevent transmission and reduce the incidence of infectious diseases due to its ability to induce trained immunity. However, it is not recommended to vaccinate with live-attenuated vaccines, such as BCG, to certain vulnerable populations including immunocompromised patients. This issue can be overcome with inactivated preparations that mediate trained immunity such as MV130. The safety of MV130 in pilot studies in patients with immunodeficiency or solid organ recipients, has been highlighted in recent studies. Based on the principles of trained immunity, it has recently been suggested that this concept can be further exploited in a next generation of anti-infectious vaccines: Trained immunity-based vaccines (TIbV). Thus, these vaccines may confer a broad protection far beyond to the nominal antigens they contain. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05208060
Study type Interventional
Source Inmunotek S.L.
Contact Miguel Casanovas Verges, MD, PhD
Phone 664277223
Email mcasanovas@inmunotek.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date June 1, 2022
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05515263 - Snack Foods and Their Impact on the Immune Response Following Influenza Vaccination N/A
Completed NCT02872311 - Open-Label Influenza Vaccine Evaluation N/A
Completed NCT01861613 - Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Phase 4
Completed NCT03982069 - Immunologic Response to FluMist vs. Flucelvax Phase 4
Recruiting NCT06041867 - Agaricus Bisporus and Influenza Vaccination Response N/A
Completed NCT03614975 - Immunologic Response to Influenza Vaccination in Children and Adolescents Phase 4
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03875703 - Post-Vaccination Biological Collection
Completed NCT00902278 - Immune Responses Induced by Different Licensed Influenza Vaccines N/A
Completed NCT00346619 - Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults Phase 1
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Active, not recruiting NCT05534893 - Effect of Blueberries on Immunity and Response to Flu Vaccination N/A
Completed NCT05970887 - Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines Phase 4
Completed NCT05706350 - Plant Stanol Esters and Influenza Vaccination N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Completed NCT02933931 - Immune Durability After VSV-EBOV Vaccination
Recruiting NCT01289535 - Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years Phase 4
Active, not recruiting NCT02441426 - Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A